Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AScalate
2018-003882-32Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of secukinumab and adalimumab in axial spondyloarthritis (axSpA) (2 arms), sponsored by Novartis. Primary endpoint: ASAS 40% response at Week 24. Started Jan 2019; status: completed.
02
Drugs
secukinumabadalimumab
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on 2018-003882-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003882-32.